Connect to a lawyer

Interlaw’s Danish Firm Advises Ascendis Pharma on Public Offering

Stay informed with all the latest news and developments at Interlaw and our strategic partners. Read all about our recent cross-border mandates, partner hires, office openings, pro bono and community activities, award wins and other achievements. For all media and press enquiries please email Imogen Lee, Interlaw's International Director of Marketing and Communications.

Interlaw’s partner firm in Denmark, Mazanti-Andersen Korsø Jensen, has assisted Ascendis Pharma, a Copenhagen-based biopharmaceutical company, complete its underwritten public offering of 4,859,154 American Depositary Shares (ADS), each of which represents one ordinary share in Ascendis Pharma at a price to the public of USD 142.00. The public offering generated gross proceeds of approximately USD 690 million.

Ascendis Pharma intends to use the net proceeds to support the clinical development, regulatory approval and commercial preparations for TransCon hGH, the company's therapy to counter pediatric growth hormone deficiency. Part of the proceeds will also be used for developing other endocrinology rare disease programs, as well as for identifying and progressing the development of new product candidates, and for working capital and general corporate purposes.

Mazanti transactions represented Ascendis Pharma A/S in connection with the transaction alongside a number of other advisers. Partner Lars Lüthjohan Jensen, led the team advising on the deal from Mazanti-Andersen Korsø Jensen.